Therefore, it is conceivable that PTEN loss, such as that mediated by inactivating PTEN gene mutation, may be one mechanism underlying the differences in immunophenotype between BRCA1- and BRCA2-deficient breast cancers. This evidence concerns the gene BRCA2 and breast carcinoma.